BOSTON–(BUSINESS WIRE)–Asteria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immune diseases, today announced that it will present preliminary data for nafinibart alfa-star at the upcoming European Academy of Dermatology & Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024.
Dr. Raffi Tashjian, Professor of Clinical Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School of Medicine at UCLA, will present a poster titled ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Preliminary Safety and Efficacy Results. The poster will be presented at the 6th e-Poster Presentation on Thursday, September 26 at 4:20 p.m. CEST.
About Asteria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to deliver life-changing therapies to patients and families affected by allergic and immune-mediated diseases. Our lead program, navenibart (STAR-0215), is a monoclonal inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal inhibitor of OX40 in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx, Facebook (NASDAQ:) and LinkedIn.
You can view the original press release on businesswire.com: https://www.businesswire.com/news/home/20240919236987/en/
Astraea:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.